NEXENTIS TECHNOLOGIES INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances
NEXENTIS TECHNOLOGIES INC. (NXTS) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances of $218.17 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-31.
Discontinued › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues · last filed 2022-03-31
- NEXENTIS TECHNOLOGIES INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for fiscal 2021 was $218.17K, a 685.85% increase from fiscal 2020.
- NEXENTIS TECHNOLOGIES INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for fiscal 2020 was $27.76K.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 12 month |
|---|---|
| 2021-12-31 | $218.17K 10-K · filed 2022-03-31 |
| 2020-12-31 | $27.76K 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |